SCHEMBL2534136

SCHEMBL2534136

FC(c1ccccc1)c1cccc(C2OCCO2)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP2C19 P33261 1/20 0.38
TSHR P16473 1/20 0.34
HTT P42858 2/20 0.33
USP19 O94966 1/20 0.32
EPHX1 P07099 1/20 0.32
ALDH1A1 P00352 2/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
KCNA4 P22459 1/20 0.30
KCNA1 Q09470 1/20 0.30
KCNAB1 Q14722 1/20 0.30
GRIN2B Q13224 1/20 0.30
LMNA P02545 1/20 0.30
SLC6A2 P23975 1/20 0.30
ADRA1A P35348 1/20 0.30
HTR2B P41595 1/20 0.30
SLC6A3 Q01959 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16148375 0.84 MEN1 (0.33) MEN1KMT2ACYP2C19HTTUSP19
SCHEMBL2535973 0.80 EPHX1 (0.39) MEN1KMT2ACYP2C19TSHRHTT
SCHEMBL5790167 0.78 HTR2A (0.50) MEN1KMT2ACYP2C19HTTUSP19
SCHEMBL27796397 0.77 ALDH1A1 (0.38) MEN1KMT2ACYP2C19HTTUSP19
SCHEMBL2936663 0.77 MEN1 (0.33) MEN1KMT2ACYP2C19HTTALDH1A1
SCHEMBL5791987 0.77 CTSD (0.39) MEN1KMT2AUSP19
SCHEMBL2934366 0.75 SRC (0.46) MEN1KMT2ACYP2C19HTTUSP19
SCHEMBL8322242 0.74 CHRNB2 (0.37) MEN1KMT2ACYP2C19USP19EPHX1
SCHEMBL2930360 0.73 HTT (0.33) MEN1KMT2ACYP2C19HTTUSP19
SCHEMBL366283 0.73 CYP2C19 (0.62) MEN1KMT2ACYP2C19TSHRKCNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 EP disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 US disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 US disclosed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B MEN1 1889/4885KMT2A 1269/4885CYP2C19 438/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B MEN1 1889/4885KMT2A 1269/4885CYP2C19 438/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B MEN1 1889/4885KMT2A 1269/4885CYP2C19 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.